Search

Search Constraints

You searched for: Author/Creator Cheng, Heather H.

Search Results

12. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. (2021)

13. Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer. Issue 3 (16th November 2022)

14. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Issue 16 (13th September 2021)

16. MP56-06 ASSOCIATIONS BETWEEN SKELETAL MUSCLE GAUGE AND SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER: A NOVEL ASSESSMENT OF MUSCLE MASS AND QUALITY. (May 2022)

17. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Issue 3 (March 2022)

18. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. (8th December 2013)

19. Undetectable prostate‐specific antigen after short‐course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis‐free survival and prostate cancer‐specific survival. Issue 14 (10th July 2018)